Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the U.S. Government AUSTIN, Texas , Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease,
1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia. Top-line results for on-going, 52-week Phase 3 trial expected approximately year-end 2024. Top-line results for on-going, 76-week Phase 3 trial expected approximately mid-year 2025.
Safety Finding Based on Blinded MRI Brain Data at Week 40 ARIA is a Known Risk Factor for Anti-Amyloid Antibody Drugs MRI Data Presented at the 16 th CTAD Conference in Boston, MA AUSTIN, Texas , Oct. 25, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.
CUNY’s report makes no findings of data manipulation. The “ egregious misconduct ” cited in the report relates to internal record-keeping failures at CUNY . CUNY’s report finds that internal record-keeping failures “ prevented us [ CUNY ] from making an objective assessment ” of research
CEO to Present on Wednesday, October 11th, at 10:30am ET AUSTIN, Texas , Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that Remi Barbier , President & Chief Executive
804 Alzheimer’s Patients Are Enrolled in a Pivotal Phase 3 Clinical Trial A Second Pivotal Phase 3 Clinical Trial Is Expected to Complete Enrollment Q4 2023, With a Target Enrollment of Approximately 1,100 Patients. AUSTIN, Texas , Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical Trials. The DSMB Recommended the Phase 3 Trials of Simufilam Continue as Planned, Without Modification AUSTIN, Texas , Sept.
New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease. Results corroborate prior research from other academic researchers. These data once again confirm the biological activity of simufilam. AUSTIN, Texas , Sept.
AUSTIN, Texas , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it has been invited to present at the following investor conferences.
